Announcements Trials
Browse Landscape

Status

Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Neoplasms 1Dwarfism, Pituitary 1Diabetes Mellitus, Type 2 1

Interventions

Everolimus 6Sunitinib 4Octreotide 4Leucovorin 4dabrafenib 3Fluorouracil 33-Iodobenzylguanidine 3trametinib 2selpercatinib 2lutetium Lu 177 dotatate 2avelumab 2alectinib 2PM 01183 2Oxaliplatin 2Irinotecan 2Fulvestrant 2Drug Therapy 2Doxorubicin 2Cisplatin 2trifluridine tipiracil drug combination 1tipifarnib 1telotristat ethyl 1surufatinib 1somapacitan 1ribociclib 1repotrectinib 1pralsetinib 1pentetreotide 1pegfilgrastim 1pasireotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × somapacitan × Endocrine × Clear all
NCT06709040 2026-04-06

A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters

Novo Nordisk A/S

Enrolling by invitation
500 enrolled
Endocrine

Diabetes Mellitus, Type 2, Dwarfism, Pituitary, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡